세계의 바이오엔지니어링 단백질 의약품 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)
Global Bioengineered Protein Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
상품코드:1481812
리서치사:Value Market Research
발행일:2024년 05월
페이지 정보:영문 234 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
바이오엔지니어링 단백질 의약품의 세계 수요는 2023년 3,467억 6,600만 달러에서 2032년 6,455억 9,000만 달러에 육박하는 시장 규모에 도달할 것으로 추정되며, 2024-2032년 조사 기간 동안 7.15%의 CAGR을 기록할 것으로 예상됩니다.
바이오엔지니어링 단백질 의약품은 생명공학 기술을 이용하여 체내에 자연적으로 존재하는 단백질을 모방한 단백질을 만들어내는 의약품입니다. 이들 의약품은 질병 과정에 관여하는 특정 생물학적 경로 또는 분자를 표적으로 삼아 자가면역질환, 암, 유전질환 등 다양한 질환에 대한 표적 치료제를 말합니다. 이들 의약품은 재조합 DNA 기술을 이용해 제조되며, 원하는 단백질을 암호화하는 유전자가 효모, 박테리아, 포유류 세포 등의 숙주 세포에 삽입되어 소형 단백질 공장 역할을 합니다. 이러한 의약품은 기존 의약품에 비해 부작용이 적고, 매우 효과적이며, 종종 보다 표적화된 치료법을 제공함으로써 의료에 혁명을 일으키고 있습니다.
시장 역학
암, 자가면역질환, 대사성 질환과 같은 만성질환이 급증하면서 기존 의약품보다 더 높은 효능과 부작용을 감소시키는 표적화된 생물학적 기반 치료제에 대한 수요가 증가하고 있습니다. 단클론항체, 사이토카인, 성장인자 등 바이오엔지니어링 단백질 의약품은 질병 경로를 정확하게 표적화하고 조절하여 환자의 예후와 삶의 질을 개선할 수 있습니다. 또한, 생명공학 및 유전공학 기술의 발전으로 효능, 특이성, 안정성이 개선된 새로운 단백질 치료제의 개발이 가능해지면서 환자와 의료진이 이용할 수 있는 치료 옵션의 폭이 넓어지고 있습니다. 또한, 바이오 제약사 및 학계의 연구개발에 대한 투자 증가는 바이오엔지니어링 단백질 의약품의 발견과 개발에서 기술 혁신을 촉진하고 새로운 약물 표적과 치료법을 발견할 수 있도록 돕고 있습니다. 또한, 개인 맞춤형 의료 접근법 및 바이오마커 기반 치료 전략의 채택이 증가함에 따라 환자 개개인의 특성과 질병 프로파일에 맞게 조정된 바이오엔지니어링 단백질 의약품에 대한 수요가 증가하고 있으며, 이는 치료 결과를 개선하고 의료 비용을 절감하는 데 도움이 될 것으로 기대됩니다. CMS와 같은 규제 당국과 지불 기관이 바이오의약품을 수용하고 있는 것은 이러한 혁신적인 치료법의 시장 진입과 상환을 촉진하여 시장 성장과 보급을 더욱 촉진하고 있습니다. 그러나 바이오의약품과 대체 치료법의 발전은 향후 몇 년 동안 시장 성장에 도전이 될 수 있습니다.
조사 보고서는 Porter's Five Forces 모델, 시장 매력도 분석, 밸류체인 분석을 다루고 있습니다. 이러한 도구는 산업 구조를 명확하게 파악하고 세계 수준에서 경쟁의 매력을 평가하는 데 도움이됩니다. 또한 이러한 도구는 바이오엔지니어링 단백질 의약품 세계 시장에서 각 부문을 포괄적으로 평가할 수 있습니다. 바이오엔지니어링 단백질 의약품 산업의 성장과 동향은 이 조사에 대한 전체적인 접근 방식을 설명합니다.
시장 세분화
바이오엔지니어링 단백질 의약품 시장 보고서는 국가 및 지역 수준의 부문에 대한 상세한 데이터를 제공하여 전략 담당자가 각 제품 및 서비스의 타겟층을 파악하고 향후 비즈니스 기회를 포착할 수 있도록 돕습니다.
약제 유형별
단클론항체(휴미라, 리툭산, 아바스틴, 허셉틴, 레미케이드, 레미케이드, 루센티스, 엔브렐, 시너시스 등)
이 섹션에서는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카의 바이오엔지니어링 단백질 의약품 시장의 현재와 미래 수요를 강조하는 지역 전망을 다룹니다. 또한, 이 보고서는 모든 주요 지역의 개별 응용 분야에 대한 수요, 추정 및 예측에 초점을 맞추고 있습니다.
맞춤형 요구사항이 있는 경우, 저희에게 연락주시기 바랍니다. 당사의 조사팀은 고객의 요구에 따라 맞춤형 보고서를 제공할 수 있습니다.
The global demand for Bioengineered Protein Drugs Market is presumed to reach the market size of nearly USD 645.59 Billion by 2032 from USD 346.76 Billion in 2023 with a CAGR of 7.15% under the study period 2024-2032.
Bioengineered protein drugs are pharmaceutical products created using biotechnology techniques to produce proteins that mimic those naturally occurring in the body. These drugs target specific biological pathways or molecules involved in disease processes, offering targeted therapies for various medical conditions such as autoimmune disorders, cancer, and genetic diseases. These drugs are produced using recombinant DNA technology, where genes encoding the desired protein are inserted into host cells such as yeast, bacteria, or mammalian cells, which act as miniature protein factories. These drugs have revolutionized medical treatment by providing highly effective and often more targeted therapies with fewer side effects compared to traditional drugs.
MARKET DYNAMICS
The proliferating prevalence of chronic diseases such as cancer, autoimmune disorders, and metabolic diseases is driving the demand for targeted and biologically-based therapies that offer enhanced efficacy & reduced side effects than traditional pharmaceuticals. Bioengineered protein drugs, including monoclonal antibodies, cytokines, and growth factors, provide precise targeting and modulation of disease pathways, leading to better patient outcomes and quality of life. Additionally, advancements in biotechnology and genetic engineering techniques allow the development of novel protein therapeutics with enhanced potency, specificity, and stability, expanding the therapeutic options available to patients and healthcare providers. Moreover, the growing investment in research and development by biopharmaceutical companies and academic institutions is driving innovation in bioengineered protein drug discovery and development, leading to the discovery of novel drug targets and therapeutic modalities. Furthermore, the increasing adoption of personalized medicine approaches and biomarker-driven treatment strategies drives demand for bioengineered protein drugs tailored to individual patient characteristics and disease profiles, improving treatment outcomes and reducing healthcare costs. The growing acceptance of bioengineered protein drugs by regulatory agencies and payers, including the FDA and CMS, facilitates market access and reimbursement for these innovative therapies, further driving market growth and adoption. However, advancements in biopharmaceuticals and alternative treatment modalities may challenge the market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Bioengineered Protein Drugs. The growth and trends of Bioengineered Protein Drugs industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Bioengineered Protein Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Bioengineered Protein Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Bioengineered Protein Drugs market include Abbott, Amgen Inc., Bayer AG, Biocon, Dr. Reddy'S Laboratories, Lilly, F. Hoffmann - La Roche Ltd., Fresenius Kabi AG, GSK, Janssen Global Services, Merck & Co. Inc., Novartis AG, Panacea Biotec, ProBioGen AG, Reliance Life Science, Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
5.6. Vaccines Historic and Forecast Sales By Regions
6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY DISEASE CONDITION
6.1. Overview By Disease Condition
6.2. Historical and Forecast Data
6.3. Analysis By Disease Condition
6.4. Cancer Historic and Forecast Sales By Regions
6.5. Diabetes Historic and Forecast Sales By Regions
6.6. Autoimmune Disorder Historic and Forecast Sales By Regions
6.7. Infectious Disease Historic and Forecast Sales By Regions
6.8. Hematopoiesis Historic and Forecast Sales By Regions
6.9. CVD Historic and Forecast Sales By Regions
6.10. Neurodegenerative Historic and Forecast Sales By Regions
6.11. Others Historic and Forecast Sales By Regions
7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY END-USER
7.1. Overview By End-user
7.2. Historical and Forecast Data
7.3. Analysis By End-user
7.4. Pharma and Biotech Companies Historic and Forecast Sales By Regions
7.5. CROs Historic and Forecast Sales By Regions
7.6. Research Institutes Historic and Forecast Sales By Regions
8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY GEOGRAPHY
8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
8.3.1 Overview, Historic and Forecast Data Sales Analysis
8.3.2 North America By Segment Sales Analysis
8.3.3 North America By Country Sales Analysis
8.3.4 United States Sales Analysis
8.3.5 Canada Sales Analysis
8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
8.4.1 Overview, Historic and Forecast Data Sales Analysis
8.4.2 Europe By Segment Sales Analysis
8.4.3 Europe By Country Sales Analysis
8.4.4 United Kingdom Sales Analysis
8.4.5 France Sales Analysis
8.4.6 Germany Sales Analysis
8.4.7 Italy Sales Analysis
8.4.8 Russia Sales Analysis
8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
8.5.1 Overview, Historic and Forecast Data Sales Analysis
8.5.2 Asia Pacific By Segment Sales Analysis
8.5.3 Asia Pacific By Country Sales Analysis
8.5.4 China Sales Analysis
8.5.5 India Sales Analysis
8.5.6 Japan Sales Analysis
8.5.7 South Korea Sales Analysis
8.5.8 Australia Sales Analysis
8.5.9 South East Asia Sales Analysis
8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
8.6.1 Overview, Historic and Forecast Data Sales Analysis
8.6.2 Latin America By Segment Sales Analysis
8.6.3 Latin America By Country Sales Analysis
8.6.4 Brazil Sales Analysis
8.6.5 Argentina Sales Analysis
8.6.6 Peru Sales Analysis
8.6.7 Chile Sales Analysis
8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
8.7.1 Overview, Historic and Forecast Data Sales Analysis
8.7.2 Middle East & Africa By Segment Sales Analysis
8.7.3 Middle East & Africa By Country Sales Analysis
8.7.4 Saudi Arabia Sales Analysis
8.7.5 UAE Sales Analysis
8.7.6 Israel Sales Analysis
8.7.7 South Africa Sales Analysis
8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE BIOENGINEERED PROTEIN DRUGS COMPANIES
9.1. Bioengineered Protein Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments
10. COMPANY PROFILES OF BIOENGINEERED PROTEIN DRUGS INDUSTRY
10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Abbott
10.3.1 Company Overview
10.3.2 Company Revenue
10.3.3 Products
10.3.4 Recent Developments
10.4. Amgen Inc.
10.4.1 Company Overview
10.4.2 Company Revenue
10.4.3 Products
10.4.4 Recent Developments
10.5. Bayer AG
10.5.1 Company Overview
10.5.2 Company Revenue
10.5.3 Products
10.5.4 Recent Developments
10.6. Biocon
10.6.1 Company Overview
10.6.2 Company Revenue
10.6.3 Products
10.6.4 Recent Developments
10.7. Dr. Reddy'S Laboratories
10.7.1 Company Overview
10.7.2 Company Revenue
10.7.3 Products
10.7.4 Recent Developments
10.8. Lilly
10.8.1 Company Overview
10.8.2 Company Revenue
10.8.3 Products
10.8.4 Recent Developments
10.9. F. Hoffmann - La Roche Ltd.
10.9.1 Company Overview
10.9.2 Company Revenue
10.9.3 Products
10.9.4 Recent Developments
10.10. Fresenius Kabi AG
10.10.1 Company Overview
10.10.2 Company Revenue
10.10.3 Products
10.10.4 Recent Developments
10.11. GSK
10.11.1 Company Overview
10.11.2 Company Revenue
10.11.3 Products
10.11.4 Recent Developments
10.12. Janssen Global Services
10.12.1 Company Overview
10.12.2 Company Revenue
10.12.3 Products
10.12.4 Recent Developments
10.13. Merck & Co. Inc.
10.13.1 Company Overview
10.13.2 Company Revenue
10.13.3 Products
10.13.4 Recent Developments
10.14. Novartis AG
10.14.1 Company Overview
10.14.2 Company Revenue
10.14.3 Products
10.14.4 Recent Developments
10.15. Panacea Biotec
10.15.1 Company Overview
10.15.2 Company Revenue
10.15.3 Products
10.15.4 Recent Developments
10.16. ProBioGen AG
10.16.1 Company Overview
10.16.2 Company Revenue
10.16.3 Products
10.16.4 Recent Developments
10.17. Reliance Life Science
10.17.1 Company Overview
10.17.2 Company Revenue
10.17.3 Products
10.17.4 Recent Developments
10.18. Sanofi
10.18.1 Company Overview
10.18.2 Company Revenue
10.18.3 Products
10.18.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
